Kamal M, Baudo M, Joseph J, Geng Y, Mohamed O, Rahouma M
Healthcare (Basel). 2024; 12(5).
PMID: 38470640
PMC: 10931059.
DOI: 10.3390/healthcare12050530.
Tailor I, Alshehry N, Zaidi S, Marei M, Motabi I, Alfayez M
Hematol Oncol Stem Cell Ther. 2023; 16(1):88-90.
PMID: 36634278
PMC: 7492149.
DOI: 10.1016/j.hemonc.2020.08.002.
Liang Y, He H, Wang W, Wang H, Mo S, Fu R
Mol Cancer. 2022; 21(1):182.
PMID: 36131282
PMC: 9492468.
DOI: 10.1186/s12943-022-01648-z.
Al Sbihi A, Manasrah N, Sano D
Eur J Case Rep Intern Med. 2022; 9(3):003216.
PMID: 35402321
PMC: 8988502.
DOI: 10.12890/2022_003216.
Scarpa R, DellEdera A, Felice C, Buso R, Muscianisi F, Gambier R
Front Immunol. 2022; 13:842643.
PMID: 35359947
PMC: 8960988.
DOI: 10.3389/fimmu.2022.842643.
New insights into genetic characteristics between multiple myeloma and COVID-19: An integrative bioinformatics analysis of gene expression omnibus microarray and the cancer genome atlas data.
Wang F, Liu R, Yang J, Chen B
Int J Lab Hematol. 2021; 43(6):1325-1333.
PMID: 34623759
PMC: 8652836.
DOI: 10.1111/ijlh.13717.
COVID-19 Virus Infection in Three Patients With Hypogammaglobulinemia.
Gesiotto Q, Cheema A, Avaiya K, Shah B, Greene J
Cureus. 2021; 13(5):e15256.
PMID: 34188994
PMC: 8231731.
DOI: 10.7759/cureus.15256.
Multimodality treatment in immunocompromised patients with severe COVID-19: the role of IL-6 inhibitor, intravenous immunoglobulin, and haemoperfusion.
Leelayuwatanakul N, Kongpolprom N, Sriprasart T, Phoophiboon V, Thanthitaweewat V, Thawanaphong S
Respirol Case Rep. 2021; 9(4):e0733.
PMID: 33732466
PMC: 7938208.
DOI: 10.1002/rcr2.733.
Continuing Cancer Therapy through the Pandemic While Protecting Our Patients: Results of the Implementation of Preventive Strategies in a Referral Oncology Unit.
Liontos M, Kastritis E, Markellos C, Migkou M, Eleftherakis-Papaiakovou E, Koutsoukos K
Cancers (Basel). 2021; 13(4).
PMID: 33673120
PMC: 7918613.
DOI: 10.3390/cancers13040763.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroconversion in hematology-oncology patients.
Bird P, Badhwar V, Kennedy B, Ladani S, Tang J
J Med Virol. 2021; 93(7):4585-4591.
PMID: 33595119
PMC: 8014444.
DOI: 10.1002/jmv.26886.
COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patients.
Belsky J, Tullius B, Lamb M, Sayegh R, Stanek J, Auletta J
J Infect. 2021; 82(3):329-338.
PMID: 33549624
PMC: 7859698.
DOI: 10.1016/j.jinf.2021.01.022.
COVID-19 in Immunocompromised Hosts: What We Know So Far.
Fung M, Babik J
Clin Infect Dis. 2021; 72(2):340-350.
PMID: 33501974
PMC: 7337668.
DOI: 10.1093/cid/ciaa863.
Tropinone-Derived Alkaloids as Potent Anticancer Agents: Synthesis, Tyrosinase Inhibition, Mechanism of Action, DFT Calculation, and Molecular Docking Studies.
Piechowska K, Mizerska-Kowalska M, Zdzisinska B, Cytarska J, Baranowska-Laczkowska A, Jaroch K
Int J Mol Sci. 2020; 21(23).
PMID: 33260768
PMC: 7731314.
DOI: 10.3390/ijms21239050.
The impact of COVID-19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single-center experience.
Lee H, Tay J, Duggan P, McCulloch S, Neri P, Bahlis N
Eur J Haematol. 2020; 106(3):340-345.
PMID: 33197297
PMC: 7753531.
DOI: 10.1111/ejh.13552.
The Outcome of Six Patients with COVID-19 Infection and Multiple Myeloma.
Elsabah H, Aldapt M, Taha R, Soliman D, Elomri H, Ibrahim F
Mediterr J Hematol Infect Dis. 2020; 12(1):e2020082.
PMID: 33194156
PMC: 7643781.
DOI: 10.4084/MJHID.2020.082.
When hematologic malignancies meet COVID-19 in the United States: Infections, death and disparities.
Wang Q, Berger N, Xu R
Blood Rev. 2020; 47:100775.
PMID: 33187811
PMC: 7833659.
DOI: 10.1016/j.blre.2020.100775.
Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
Giesen N, Sprute R, Ruthrich M, Khodamoradi Y, Mellinghoff S, Beutel G
Eur J Cancer. 2020; 140:86-104.
PMID: 33068941
PMC: 7505554.
DOI: 10.1016/j.ejca.2020.09.009.
